| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Abbott Laboratories (NYSE: ABT)
ABT Technical Analysis
4
| As on 31st Oct 2017 ABT Share Price closed @ 54.23 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 46.30 & Buy for SHORT-TERM with Stoploss of 52.65 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ABT Share Price
| Open | 54.48 | Change | Price | % |
| High | 54.54 | 1 Day | -0.06 | -0.11 |
| Low | 54.03 | 1 Week | 0.00 | 0.00 |
| Close | 54.23 | 1 Month | -0.42 | -0.77 |
| Volume | 7676194 | 1 Year | 14.09 | 35.10 |
| 52 Week High 56.69 | 52 Week Low 37.38 | ||||
NYSE USA Most Active Stocks
| RAI | 65.40 | -2.23% |
| EMC | 29.05 | 0.97% |
| GE | 20.16 | -1.22% |
| AKS | 4.59 | -21.54% |
| PCS | 11.84 | -0.92% |
| AMD | 10.98 | 0.83% |
| WSH | 47.18 | -2.86% |
| JNS | 14.17 | -0.56% |
| XLS | 24.66 | -0.64% |
| SWY | 35.10 | -0.11% |
NYSE USA Top Gainers Stocks
NYSE USA Top Losers Stocks
| ABT Daily Charts |
ABT Intraday Charts |
Whats New @ Bazaartrend |
ABT Free Analysis |
|
|
ABT Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| RESISTANCE | 54.70 |
| RESISTANCE | 54.51 |
| SUPPORT | 53.95 |
| SUPPORT | 53.76 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
ABT Target for Month August
| 4th UP TARGET | 60.97 |
| 3rd UP TARGET | 58.81 |
| 2nd UP TARGET | 57.47 |
| 1st UP TARGET | 56.14 |
| 1st DOWN TARGET | 52.32 |
| 2nd DOWN TARGET | 50.99 |
| 3rd DOWN TARGET | 49.65 |
| 4th DOWN TARGET | 47.49 |
ABT Weekly Target
| 4th UP TARGET | 0.00 |
| 3rd UP TARGET | 0.00 |
| 2nd UP TARGET | 0.00 |
| 1st UP TARGET | 0.00 |
| 1st DOWN TARGET | 0.00 |
| 2nd DOWN TARGET | 0.00 |
| 3rd DOWN TARGET | 0.00 |
| 4th DOWN TARGET | 0.00 |
ABT Target for Year 2021
| 4th UP TARGET | 0 |
| 3rd UP TARGET | 0 |
| 2nd UP TARGET | 0 |
| 1st UP TARGET | 0 |
| 1st DOWN TARGET | 0 |
| 2nd DOWN TARGET | 0 |
| 3rd DOWN TARGET | 0 |
| 4th DOWN TARGET | 0 |
Abbott Laboratories ( NYSE USA Symbol : ABT )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ABT Business Profile
Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome, intrahepatic cholestasis or depressive symptoms, gynecological disorders, dyslipidemia, hypertension, hypothyroidism, pain, fever, and inflammation; and regulates physiological rhythm of the colon, as well as provides hormone replacement therapy and anti-infective and influenza vaccines. The companys Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products comprising various forms of prepared infant and follow-on formula. The companys Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular diseases. Abbott Laboratories also offers blood glucose and glucose monitoring systems, test strips, and data management software and accessories for people with diabetes; and medical devices for the eye, including cataract surgery, LASIK surgery, contact lens care products, and dry eye products. The company primarily serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians offices, and government agencies. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
